Evorpacept (ALX148) + Pembrolizumab + Trastuzumab + Rituximab + Ramucirumab + Paclitaxel + 5-FU + Cisplatin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Cancer
Conditions
Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
Trial Timeline
Feb 3, 2017 → Jul 8, 2025
NCT ID
NCT03013218About Evorpacept (ALX148) + Pembrolizumab + Trastuzumab + Rituximab + Ramucirumab + Paclitaxel + 5-FU + Cisplatin
Evorpacept (ALX148) + Pembrolizumab + Trastuzumab + Rituximab + Ramucirumab + Paclitaxel + 5-FU + Cisplatin is a phase 1 stage product being developed by ALX Oncology for Metastatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03013218. Target conditions include Metastatic Cancer, Solid Tumor, Advanced Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03013218 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Cancer